Praxis Precision Medicines, Inc. PRAX Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost

Other financials

Revenue--100%

Operating income-$105.9M-41.7%

Net income-$92.6M-33.6%

EPS (diluted)-$3.20+2.7%

Cash & equivalents$536.7M+223%

Total debt$1.4M+31.3%

Total equity$1.4B+221%

Total assets$1.5B+205%

Operating cash flow-$86.2M-62.5%

CapEx$62.0K—

Free cash flow-$86.2M-62.6%

Market cap$7.87B+1,075%

Enterprise value$7.34B+1,309%

Operating margin-3,927.5%-1,497pp

Net margin-3,658.5%-1,388pp

FCF margin-3,067.4%-1,030pp

Return on equity-35.3%-10.9pp

Debt / equity0×0.0×

Current ratio15.9×+7.4×

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept prax:CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Praxis Precision Medicines, Inc.'s cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost?: Praxis Precision Medicines, Inc. (PRAX) reported cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost of $1.16B in Q1 2026.
How has Praxis Precision Medicines, Inc.'s cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost changed year-over-year?: Praxis Precision Medicines, Inc.'s cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost increased by 189.8% year-over-year, from $399.84M to $1.16B.